University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Victoria Wang, MD, PhD

Victoria Wang, MD, PhD

Clinical Instructor, Division of Hematology/Oncology, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Education

Stanford University, BAS/ MS, 1995, Biological Sciences and Asian Languages
Massachusetts Institute of Technology, PhD, 2003, Biology
Harvard Medical School, MD, 2006, Medicine
Stanford University Hospital, Intern, 2007, Internal Medicine
Brigham and Women’s Hospital, Resident, 2009, Radiation Oncology
Massachusetts General Hospital, Resident, 2011, Internal Medicine
University of California, San Francisco, Fellow, 2018, Hematology-Oncology


Professional Experience

  • 1993 - 1995
    Teaching Assistant in Chemistry, Stanford
  • 1995 - 1995
    Summer Intern, Amgen
  • 1996 - 1997
    Teaching Assistant in Chemistry, Harvard
  • 2006 - 2007
    Intern in Medicine, Stanford
  • 2007 - 2009
    Resident in Radiation Oncology, Brigham and Women’s Hospital
  • 2009 - 2011
    Resident in Medicine, Massachusetts General Hospital
  • 2011 - 2018
    Fellow in Hematology and Oncology, University of California, San Francisco
  • 2018 - present
    Clinical Instructor, University of California, San Francisco

Honors & Awards

  • 1997-2000
    Howard Hughes Predoctoral Fellowship
  • 1998
    MIT Graduate Student Teaching Award
  • 2000
    International Achievement Summit
  • 2002-2003
    David Koch Graduate Fellowship, MIT
  • 2003-2005
    MSTP Fellowship, Harvard Medical School
  • 2006
    James Tolbert Shipley Prize for Excellence in Research, Harvard Medical School
  • 2010
    AACR Molecular Biology in Clinical Oncology course in Aspen, CO
  • 2012
    AACR Methods in Clinical Cancer Research course in Vail, CO
  • 2013
    AACR-Amgen Clinical and Translational Fellowship
  • 2013-2017
    Damon Runyon Postdoctoral Fellowship
  • 2014, 2015
    Lung Cancer Research Foundation Fellowship
  • 2016
    ASCO-Young Investigator Award
  • 2017
    Burroughs Wellcome Career Award for Medical Scientist Finalist
  • 2017
    AACR Scholar-in-Training Travel Award
  • 2017
    ASCO Young Investigator Forum Top Presenter

Selected Publications

  1. Wang VE, Schmidt T, Chen J, Sharp PA, Tantin D. Embryonic lethality, decreasederythropoiesis, and defective octamer-dependent promoter activation inOct-1-deficient mice. Mol Cell Biol. 2004 Feb;24(3):1022-32. PubMed [citation]PMID: 14729950, PMCID: PMC321444
  2. Nogueira ML, Wang VE, Tantin D, Sharp PA, Kristie TM. Herpes simplex virusinfections are arrested in Oct-1-deficient cells. Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1473-8. Epub 2004 Jan 26. PubMed [citation] PMID: 14745036, PMCID: PMC341744
  3. Wang VE, Tantin D, Chen J, Sharp PA. B cell development and immunoglobulintranscription in Oct-1-deficient mice. Proc Natl Acad Sci U S A. 2004 Feb17;101(7):2005-10. Epub 2004 Feb 4. PubMed [citation] PMID: 14762167, PMCID:PMC357042
  4. Tantin D, Schild-Poulter C, Wang V, Haché RJ, Sharp PA. The octamer bindingtranscription factor Oct-1 is a stress sensor. Cancer Res. 2005 Dec1;65(23):10750-8. PubMed [citation] PMID: 16322220
  5. Shakya A, Cooksey R, Cox JE, Wang V, McClain DA, Tantin D. Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. Nat Cell Biol. 2009 Mar;11(3):320-7. doi: 10.1038/ncb1840. Epub 2009 Feb 15. PubMed [citation]PMID: 19219035
  6. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J,Sidhu H, Uzgiris A, Rugo HS, Park JW. A Novel Strategy for Detection andEnumeration of Circulating Rare Cell Populations in Metastatic Cancer PatientsUsing Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015Oct 23;10(10):e0141166. doi: 10.1371/journal.pone.0141166. eCollection 2015.PubMed [citation] PMID: 26496203, PMCID: PMC4619669
  7. Wang VE, Grandis JR, Ko AH. New Strategies in Esophageal Carcinoma: TranslationalInsights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res. 2016Sep 1;22(17):4283-90. doi: 10.1158/1078-0432.CCR-16-0292. Epub 2016 Jul 1.Review. PubMed [citation] PMID: 27370606
  8. Wang V, Bivona T, Ali SM, Schrock AB, Miller VA. CD74-ROS1 Fusion inNSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays.J Thorac Oncol. 2017 Feb;12(2):e19-e20. doi: 10.1016/j.jtho.2016.11.2217. Noabstract available. PubMed [citation] PMID: 28115114
  9. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, FoghS, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALKTranslocation and Diffuse Brain Metastases. Oncologist. 2017 Jul;22(7):768-773.doi: 10.1634/theoncologist.2017-0054. Epub 2017 May 15. PubMed [citation] PMID:28507205, PMCID: PMC5507651
  10. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D.Checkpoint inhibitor is active against large cell neuroendocrine carcinoma withhigh tumor mutation burden. J Immunother Cancer. 2017 Sep 19;5(1):75. doi:10.1186/s40425-017-0281-y. PubMed [citation] PMID: 28923100, PMCID: PMC5604145
  11. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N,Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, BanksKC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD,Mack PC, et al. Evolution and clinical impact of co-occurring genetic alterationsin advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec;49(12):1693-1704.doi: 10.1038/ng.3990. Epub 2017 Nov 6. PubMed [citation] PMID: 29106415, PMCID:PMC5709185
  12. Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, BardiaA, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP,Polyak K, Lin NU. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, inpatients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018. PubMed [citation]PMID: 29761158, PMCID: PMC5935675
  13. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G,Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, et al.Aurora kinase A drives the evolution of resistance to third-generation EGFRinhibitors in lung cancer. Nat Med. 2019 Jan;25(1):111-118. doi:10.1038/s41591-018-0264-7. Epub 2018 Nov 26. PubMed [citation] PMID: 30478424,PMCID: PMC6324945